Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Here, John DiPersio, MD, PhD, of Washington University School of Medicine, St. Louis, MO, talks about JAK pathway inhibitors for the treatment and prevention of graft-versus-host disease. Dr DiPersio was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.
We use necessary cookies to make this site work. Analytics, preference, and marketing cookies are used only if you choose to allow them. You can change your choice at any time. For more information view our Cookie Policy.